Safety and Pharmacokinetic Study of Tenofovir Alafenamide (TAF)/Elvitegravir (EVC) Administered Rectally
Status:
Completed
Trial end date:
2021-04-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and pharmacokinetics of rectal
administration of a tenofovir alafenamide (TAF)/elvitegravir (EVG) insert at two dose levels
in HIV-uninfected individuals.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)